Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Marketed and Pipeline Drugs Report Overview
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a type of acquired immune-mediated disorder that affects the myelin components of the peripheral nervous system. CIDP can be monophasic, relapsing, or progressive, developing over eight weeks. People with CIDP experience fatigue, muscle weakness, and a loss of feeling symmetrically in their arms and legs that tends to slowly worsen over time.
The CIDP marketed and pipeline drugs market research report provides a data-driven overview of the current and future competitive landscape in CIDP therapeutics. This report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, pricing and reimbursement, late-stage pipeline products with phase transition success rate (PTSR), and the likelihood of approval (LoA) for CIDP.
Leading Marketed Drugs for CIDP
High-dose IVIg is the only drug that has approval in the US, Canada, and Europe for the treatment of CIDP. Other first-line options include corticosteroids and plasma exchange. Depending on the country, these therapies may be tried before opting for IVIg.
CIDP Marketed Drugs Segmentation by Mechanism of Action
The key mechanism of action for CIDP marketed drugs are receptor agonist and enzyme inhibitor. Receptor agonist is the leading MoA.
CIDP Marketed Drugs Analysis, by Mechanism of Action
For more MoA insights into the CIDP marketed drugs, download a free report sample
CIDP Marketed Drugs Segmentation by Routes of Administration
The key routes of administration for CIDP marketed drugs are oral, injection, and topical. Oral is the most preferred mode of administration.
CIDP Marketed Drugs Analysis, by Routes of Administration
For more RoA insights into the CIDP marketed drugs, download a free report sample
CIDP Marketed Drugs Segmentation by Molecule Type
The key molecule types for marketed drugs for CIDP are small molecule and biologics. Among them, small molecule is the leading one.
CIDP Marketed Drugs Analysis, by Molecule type
For more molecule type insights into the CIDP marketed drugs, download a free report sample
Leading Pipeline Drugs for CIDP
Some of the leading pipeline drugs of CIDP are immune globulin, hyaluronidase + immune globulin, forigerimod acetate, efgartigimod alfa, nipocalimab, rozanolixizumab, SAR-445088, and rituximab.
CIDP Pipeline Drugs Segmentation by Mechanism of Action
Some of the key mechanisms of action for CIDP pipeline drugs are receptor agonist, cytotoxic to cell, enzyme inhibitor, protein and peptide inhibitor, and receptor agonist. Receptor agonist is the leading MoA in the pipeline.
CIDP Pipeline Drugs Analysis, by Mechanisms of Action
For more MoA insights into the CIDP pipeline drugs market, download a free report sample
CIDP Pipeline Drugs Segmentation by Routes of Administration
The key route of administration for CIDP pipeline drugs is Injection.
CIDP Pipeline Drugs Segmentation by Molecule Type
The key molecule type for CIDP pipeline drugs is Biologics.
Top Sponsors in the CIDP Marketed and Pipeline Drugs Market
Some of the top sponsors in the CIDP marketed and pipeline drugs market are Takeda, Octapharma, Immupharma, Argenx, Zai Lab, Johnson & Johnson, UCB, Sanofi, Zenyaku Kogyo Co, Grifols, Biotest, Biocon, KM Biologics, and others.
CIDP Marketed Drugs Report Overview
| Key Mechanisms of Action | Receptor Agonist and Enzyme Inhibitor |
| Key Routes of Administration | Topical, Oral, and Injection |
| Key Molecule Types | Small Molecule and Biologics |
CIDP Pipeline Drugs Market Report Overview
| Key Mechanisms of Action | Receptor Agonist, Cytotoxic to Cell, Enzyme Inhibitor, Protein and Peptide Inhibitor, and Receptor Agonist |
| Key Routes of Administration | Injection |
| Key Molecule Types | Biologics |
| Top Sponsors (Marketed and
Pipeline Drugs) |
Takeda, Octapharma, Immupharma, Argenx, Zai Lab, Johnson & Johnson, UCB, Sanofi, Zenyaku Kogyo Co, Grifols, Biotest, Biocon, KM Biologics, and others |
Scope
GlobalData’s CIDP Marketed and Pipeline Drugs Assessment, Clinical Trials, and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Retail or Manufacturer Price of Products
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the CIDP market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CIDP market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently Asked Questions
The key mechanisms of action for CIDP marketed drugs are receptor agonist and enzyme inhibitor.
The key routes of administration for CIDP marketed drugs are topical, oral, and injection.
The key molecule types for CIDP marketed drugs are small molecule and biologics.
The key mechanisms of action in the CIDP pipeline drugs market are receptor agonist, cytotoxic to cell, enzyme inhibitor, protein and peptide inhibitor, and receptor agonist.
The key route of administration in the CIDP pipeline drugs market is injection.
The key molecule type in the CIDP pipeline drugs market is biologics.
Get in touch to find out about our multi-purchase discounts
reportstore@globaldata.com
Tel +44 (0) 20 7947 2960
Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.
Still undecided about purchasing this report?
Testimonial
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.